Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Curcio

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Genetics|April 30, 1998
Posttranslational inhibition of Ty1 retrotransposition by nucleotide excision repair/transcription factor TFIIH subunits Ssl2p and Rad3pB S Lee, C P Lichtenstein, B Faiola, et al.
Leukemia|February 13, 2002
Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodiesD Ma, M R McDevitt, E Barendswaard, et al.
Science (New York, N.Y.)|November 17, 2001
Tumor therapy with targeted atomic nanogeneratorsM R McDevitt, D Ma, L T Lai, et al.
Cancer Research|November 21, 2000
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancerM R McDevitt, E Barendswaard, D Ma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 1999
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistryT K Nikula, M R McDevitt, R D Finn, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Genetics|April 30, 1998
Posttranslational inhibition of Ty1 retrotransposition by nucleotide excision repair/transcription factor TFIIH subunits Ssl2p and Rad3pB S Lee, C P Lichtenstein, B Faiola, et al.
Leukemia|February 13, 2002
Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodiesD Ma, M R McDevitt, E Barendswaard, et al.
Science (New York, N.Y.)|November 17, 2001
Tumor therapy with targeted atomic nanogeneratorsM R McDevitt, D Ma, L T Lai, et al.
Cancer Research|November 21, 2000
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancerM R McDevitt, E Barendswaard, D Ma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 1999
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistryT K Nikula, M R McDevitt, R D Finn, et al.
Pageof 3